About us |  Subscription |  Top cited articles |  e-Alerts  | Feedback |  Login   
  Home | Ahead of print | Current Issue | Archives | Search | Instructions Celebrating 60 Years   Print this article Email this article   Small font sizeDefault font sizeIncrease font size
 
 Official publication of All India Ophthalmological Society   Users Online: 82
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (1,919 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed1138    
    Printed38    
    Emailed0    
    PDF Downloaded118    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 


 
  Table of Contents  
LETTER TO EDITOR
Year : 2011  |  Volume : 59  |  Issue : 1  |  Page : 73-74
 

Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity


Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore - 641 014, Tamilnadu, India

Date of Web Publication16-Dec-2010

Correspondence Address:
Parag K Shah
Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital, Avinashi Road, Coimbatore- 641 014, Tamil Nadu
India
Login to access the Email id


DOI: 10.4103/0301-4738.73707

PMID: 21157086

Get Permissions

 



How to cite this article:
Shah PK, Morris RJ, Narendran V, Kalpana N. Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2011;59:73-4

How to cite this URL:
Shah PK, Morris RJ, Narendran V, Kalpana N. Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol [serial online] 2011 [cited 2014 Apr 23];59:73-4. Available from: http://www.ijo.in/text.asp?2011/59/1/73/73707 DOI:10.4103/0301-4738.73707


Dear Editor,

We reported the first case of intravitreal injection of bevacizumab (Avastin, Genentech, San Francisco, CA, USA) in aggressive posterior retinopathy of prematurity (APROP) in 2007. [1] Now we report visual acuity and electroretinography (ERG) findings of the same case, 3 ΍ years after the initial injection.

A male born at 31 weeks of gestation and having a birth weight of 1170 g was diagnosed to have APROP. Immediate laser was done with almost 3,000 spots in each eye. One week after laser, both eyes developed anterior segment ischemia which was more severe in the left eye (LE). After taking an informed consent from the parents 0.03 ml bevacizumab (0.75 mg) was given intravitreally in LE. Right eye (RE) was managed conservatively. The features of anterior segment ischemia disappeared dramatically in LE after a single injection of bevacizumab, and at 10-month follow-up, fundus of both eyes showed regressed retinopathy of prematurity (ROP) with peripheral laser scars [Figure 1]. Both eyes also developed lamellar cataracts which was more in LE. [1] The cataract in LE progressed further and retinoscopy increased to -21 diopters (D) in both the axes. The RE retinoscopy was -1.5 D. The axial length was 21.2 mm in LE and 18.7 mm in RE. Cataract surgery with primary posterior capsulorhexis, anterior vitrectomy, and posterior chamber intraocular lens implantation was done in LE. One month postsurgery his visual acuity was 20/180 in RE and 20/360 in LE on Teller's acuity chart. He was advised occlusion of RE for 6 h/day for 4 months. At 3 ΍ year follow-up, best corrected visual acuity was 20/30 in RE and only 20/500 in LE on Snellen acuity chart. There was no development delay seen in this child, and clinically the central nervous system, pulmonary, gastrointestinal, and renal systems were normal. Electro retinography (ERG) was done under general anesthesia. It showed subnormal and nearly extinguished B-wave in both eyes indicating extensive damage to rods and bipolar cells. The oscillatory potential response was present in both eyes, indicating near-normal vascularity. The cone response was noted as better than the rod response as indicated by the subnormal flicker ERG cone response. All the responses, although poor, were symmetrical in both eyes [Figure 2].
Figure 1: Retcam pictures showing regressed retinopathy of prematurity (ROP) in both eyes with peripheral laser scars extending till zone 1. Bevacizumab was given in left eye

Click here to view
Figure 2: Ganzfeld session summary of both eyes showing symmetrical subnormal electroretinography (ERG) waves

Click here to view


ERG changes are seen in ROP irrespective of laser treatment. Postlaser treatment, both rods [2] and cones get affected, although rods are affected more than cones. [3] More severe the ROP, more involved are the photoreceptors. [3] Since our case had a severe form of APROP and extensively lasered, the ERG was expected to be subnormal. Although bevacizumab was given in LE, the ERG waves were comparable to RE. However the visual acuity was poor, compared to the other eye. This poor visual acuity could be a side effect of bevacizumab or may be due to amblyopia.

Our report suggests that intravitreal bevacizumab does not have an adverse effect on the ERG but could have on the final visual acuity. Thus, we urge caution in using it in premature babies till formal controlled studies with long-term follow-up are conducted to determine its potential safety in ROP.

 
   References Top

1.Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Ind J Ophthalmol 2007;55:75-6.  Back to cited text no. 1
    
2.Fulton AB, Hansen RM, Petersen RA, Vanderveen DK. The rod photoreceptors in retinopathy of prematurity. Arch Ophthalmol 2001;119:499-505.  Back to cited text no. 2
[PUBMED]    
3.Fulton AB, Hansen RM, Moskowitz. The cone electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 2008;49:814-9.  Back to cited text no. 3
    


    Figures

  [Figure 1], [Figure 2]


This article has been cited by
1 Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity
Sengul Ozdek,Metin Unlu,Gokhan Gurelik,Berati Hasanreisoglu
Journal of Optometry. 2013; 6(1): 51
[Pubmed]
2 Pharmakologische Therapie der Frühgeborenenretinopathie
A. Stahl,H. Agostini,C. Jandeck,W. Lagrèze
Der Ophthalmologe. 2011; 108(8): 777
[Pubmed]
3 Pharmacological treatment for retinopathy of prematurity | [Pharmakologische Therapie der Frühgeborenenretinopathie]
Stahl, A., Agostini, H., Jandeck, C., Lagrèze, W.
Spektrum der Augenheilkunde. 2011; 25(5): 319-330
[Pubmed]
4 Pharmakologische Therapie der Frühgeborenenretinopathie
A. Stahl,H. Agostini,C. Jandeck,W. Lagrèze
Spektrum der Augenheilkunde. 2011; 25(5): 319
[Pubmed]



 

Top
Print this article  Email this article
 

    

© 2005 - Indian Journal of Ophthalmology
Published by Medknow

Online since 1st April '05